Acquisition of Molecular Insight Pharmaceuticals, Inc (Tables)

9 Months Ended

Sep. 30, 2013

Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]

Schedule Purchase Price Allocation [Table Text Block]

	Amount
Consideration:
Progenics common stock consideration	$	11,265
Contingent consideration (pursuant to future milestone obligations)		15,900
Total consideration		27,165
Tangible assets acquired and liabilities assumed:
Cash and cash equivalents		1,888
Accounts receivable		56
Other current assets		529
Fixed assets		249
Accounts payable, accrued expenses and deferred revenue - current		(2,876	)
Deferred tax liability – long term		(12,683	)
Total tangible assets acquired and liabilities assumed		(12,837	)
Intangible assets - in process research and development		32,300
Total tangible and intangible assets acquired and liabilities assumed		19,463
Goodwill	$	7,702

Business Acquisition, Pro Forma Information

	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Revenues	$	867		$	1,286		$	4,899		$	5,434
Net loss		(10,500	)		(16,408	)		(35,185	)		(54,419	)
Basic and diluted loss per share		(0.17	)		(0.43	)		(0.65	)		(1.42	)